Search results
Results From The WOW.Com Content Network
Peak-to-trough ratio in pharmacokinetics is the ratio of peak (C max) and trough (C min) levels of a drug over its dosing interval (τ) at steady state.. Peak-to-trough ratio (PTR), also known as peak-to-trough variation or peak-to-trough fluctuation, is a parameter in pharmacokinetics which is defined as the ratio of C max (peak) concentration and C min (trough) concentration over a dosing ...
However, if a delay is observed between the drug administration and the drug effect, a temporal dissociation needs to be taken into account and more complex models exist: [6] [7] Direct vs Indirect link PK/PD models; Direct vs Indirect response PK/PD models [8] Time variant vs time invariant; Cell lifespan models; Complex response models
In pharmacokinetics, the drug accumulation ratio (R ac) is the ratio of accumulation of a drug under steady state conditions (i.e., after repeated administration) as compared to a single dose. The higher the value, the more the drug accumulates in the body. An R ac of 1 means no accumulation.
In practice, the drug concentration is measured at certain discrete points in time and the trapezoidal rule is used to estimate AUC. In pharmacology, the area under the plot of plasma concentration of a drug versus time after dosage (called “area under the curve” or AUC) gives insight into the extent of exposure to a drug and its clearance ...
English: A rational scale to assess the harm of drugs. Data source is the March 24, 2007 article: Nutt, David, Leslie A King, William Saulsbury, Colin Blakemore. "Development of a rational scale to assess the harm of drugs of potential misuse" The Lancet 2007; 369:1047-1053.
It is defined as the inverse of the absolute risk increase, and computed as / (), where is the incidence in the treated (exposed) group, and is the incidence in the control (unexposed) group. [1] Intuitively, the lower the number needed to harm, the worse the risk factor, with 1 meaning that every exposed person is harmed.
Lipinski's rule of five, also known as Pfizer's rule of five or simply the rule of five (RO5), is a rule of thumb to evaluate druglikeness or determine if a chemical compound with a certain pharmacological or biological activity has chemical properties and physical properties that would likely make it an orally active drug in humans.
High potency (high value of pIC 50) is a desirable attribute in drug candidates, as it reduces the risk of non-specific, off-target pharmacology at a given concentration. When associated with low clearance, high potency also allows for low total dose, which lowers the risk of idiosyncratic drug reaction .